Ovid Therapeutics Inc.

Ovid Therapeutics Inc. is a U.S.-based biopharmaceutical company focused on developing small-molecule medicines for brain conditions with significant unmet need. Its business centers on discovering, developing, and seeking regulatory approval for therapies in epilepsy and other neurological disorders, often through internal programs and licensing or collaboration arrangements.

−581,4 %

−240,1 %

+1 181,3 %

8.97

8.97

— Ovid Therapeutics Inc.
%
Neurology drug candidates0% Small-molecule therapies being developed for epilepsy and other brain disorders.
Licensing and collaboration revenue100% Upfront, milestone, royalty, and other payments from partnered programs.
Research and development programs0% Internal discovery, preclinical, and clinical development activities for pipeline assets.

Ovid does not sell commercial drugs today; its economic counterparties are primarily licensing partners, collaborators,...

  • Licensing and collaboration partnersprimary

    Biopharma counterparties that license rights to Ovid programs or share development economics.

  • Future prescriberssecondary

    Neurologists and other specialists who would prescribe approved therapies based on efficacy and safety.

  • Future patients and caregiverssecondary

    Patients with epilepsy and other neurological disorders who would use approved medicines.

  • Third-party payorssecondary

    Commercial and government payors that influence access, coverage, and reimbursement.

Ovid is headquartered in the United States and operates as a U.S.-based development-stage biopharmaceutical company...

  • •Headquartered in the United States
  • •Primary operating base is U.S. biopharma development
  • •Clinical trials may be conducted in multiple countries
  • •Future commercialization would depend on approved market geographies
  • •Partnering and regulatory exposure can extend beyond the U.S.

Ovid’s strategy is to advance a focused pipeline of small-molecule medicines for brain conditions with significant...

01
Advance clinical and preclinical neuroscience programsmedium-term

Pipeline progress is the main driver of future value in a development-stage biotech model.

02
Use collaborations and licensing to fund developmentshort-term

Partnership economics can provide non-dilutive capital and external validation.

03
Allocate capital selectively across programsshort-term

A focused funding approach helps concentrate resources on the most promising assets.

Ovid faces the core risks of a development-stage biotech company: clinical failure, regulatory delay, and uncertainty...

high

Need for additional capital

Development-stage operations require ongoing funding and capital may not be available on acceptable terms.

Scope
Operations and pipeline funding
Materiality
high
high

Clinical development failure

Drug candidates can fail on efficacy, safety, enrollment, or trial design.

Scope
Pipeline programs
Materiality
high
high

Regulatory approval risk

FDA and other regulators may delay, restrict, or deny approval.

Scope
All product candidates
Materiality
high
high

Third-party manufacturing dependence

The company does not own manufacturing facilities and relies on external suppliers.

Scope
Clinical and future commercial supply
Materiality
high
high

Competitive pressure

Larger pharma and biotech firms may develop better or faster therapies.

Scope
Neurology and epilepsy programs
Materiality
high
medium

Reimbursement and market access risk

Payor coverage and pricing can limit adoption even if a drug is approved.

Scope
Future commercial products
Materiality
medium
Revenue recognition for licensing and collaboration agreements
Can create uneven revenue recognition across periods
Accrued clinical and development expenses
Affects R&D expense and liabilities
Stock-based compensation
Impacts operating loss and comparability
Royalty monetization or collaboration-related liabilities
Can add volatility below operating income

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

Oncotelic Therapeutics, Inc.

OTLC · Pharmaceutical Preparations

ORAGENICS INC

OGEN · Pharmaceutical Preparations

Avidity Biosciences, Inc.

Pharmaceutical Preparations

vTv Therapeutics Inc.

VTVT · Pharmaceutical Preparations

BIOVIE INC.

BIVI · Pharmaceutical Preparations

: 29/04/2026